ERBB2 and breast cancer: Of the 27 cases we originally tested, TP53 for basal-like and HER2-enriched breast cancer, CDH1 for luminal A breast cancer and PIK2CA for luminal A and luminal B were each mutated in > 50 patients in the TCGA cohort.